(NASDAQ: VIR) Vir Biotechnology's forecast annual revenue growth rate of 59.09% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 112.96%, and while it is forecast to beat the US market's average forecast revenue growth rate of 23%.
Vir Biotechnology's revenue in 2026 is $16,860,000.On average, 11 Wall Street analysts forecast VIR's revenue for 2026 to be $1,305,688,425, with the lowest VIR revenue forecast at $136,342,531, and the highest VIR revenue forecast at $2,644,071,233. On average, 10 Wall Street analysts forecast VIR's revenue for 2027 to be $2,084,232,104, with the lowest VIR revenue forecast at $136,342,531, and the highest VIR revenue forecast at $5,580,305,034.
In 2028, VIR is forecast to generate $11,359,837,113 in revenue, with the lowest revenue forecast at -$204,513,797 and the highest revenue forecast at $51,975,720,705.